The Japan Patent Office (JPO) has introduced a measure known as "service by publication" for documents that cannot be delivered to the intended recipient, by instead publishing the relevant information in the Official Gazette and the Patent Gazette, posting the information at the JPO or making the information accessible by other such means.
The Japan Patent Office (JPO), together with the USPTO, the EPO, the CNIPA and the KIPO, has published a comparison table that summarizes the laws, examination guidelines and exemplary cases concerning AI-related inventions, which was approved by the five offices (IP5 Offices) in June 2023.
The Grand Panel found that production of a system composed of a server located abroad and domestic user terminals constituted infringement of Japanese Patent No. 6526304, owned by Dwango, the appellant, the patent being directed to an invention of a system comprising a server and plural terminal devices connected by a network.
On February 13, 2023, the Japan Patent Office (JPO) announced that the JPO will introduce a measure that allows applicants of patent applications to request suspension of examination of divisional applications filed from applications that are pending trial (appeal) proceedings.
The present case is an IP High Court Grand Panel case in which the court upheld the cumulative application of clauses (2) and (3) of Article 102 for the presumption of the amount of damages.
On July 15, 2022, a Cabinet Order announcing the dates of implementation of some of the previously reported revisions to the IP Laws was approved by the Cabinet.
As agreed by the WIPO member states, all sequence listings accompanying patent applications filed in the JPO on or after July 1, 2022, will be required to comply with WIPO Standard ST.26.
Hitherto, multiple dependent claims in patent or utility model applications that depend from other multiple dependent claims have been permitted in Japan.
As you may be aware, it usually takes about 11 to 14 months from the filing date of an application before the Japan Patent Office (JPO) issues either a first Office Action or a Notice of Allowance in a trademark application.
The Japan Patent Office (JPO) has announced relief measures regarding the handling of procedures related to patents, utility models, designs and trademarks that are affected by the novel coronavirus, COVID-19.
On April 3, 2020, the Japan Patent Office (JPO) made an announcement regarding the effect of COVID-19 on procedures such as the filing of patents, utility models, designs and trademarks.
In the present case, an inventive step of an invention relating to an ophthalmic formulation containing a doxepin derivative for treating allergic eye diseases was at issue.
This case was a lawsuit against a revocation decision made in an opposition to grant of patent. The key issue in the case concerned whether or not a "System for Providing a Steak" constitutes an invention under the patent law of Japan.
This case was a suit against a Trial Decision that dismissed a request for invalidation. One of the key issues in the case concerned the support requirement as applied to an invention defined by parameters (a "parameter invention").
From April 2018, the Japan Patent Office (JPO) is carrying out examination of patent applications in accordance with the Examination Guidelines and the Examination Handbook which have been revised regarding "eligibility for a patent" and "inventive step" with respect to software related inventions.
The Japan Patent Office has issued its annual report for FY 2017, which is available at the following URL. The main features of the report are summarized below.
The Japan Patent Office (JPO) has published statistics related to the use of the patent opposition system that has been in operation in Japan since April 2015. These are summarized below.
The Japan Patent Office has adopted the following measures in order to augment and clarify its approach to inventions related to the Internet of Things (IoT).
The "Ball Spline bearing" case of 1998 (Supreme Court Decision, 1994 (Wo) 1083) ruled that the following five conditions must be met for equivalent infringement.
Article 67(2) of the Patent Law allows for the filing of an application for extension of the duration of a patent right by not more than 5 years for pharmaceutical products, pharmaceutical apparatus and the like that require the approval of the relevant authorities.
In this case, the issue was whether or not the following product-by-process claim (hereinafter, "PBP claim") of the patent right owned by the plaintiff had been infringed.
